PE20071314A1 - Dominios kunitz quimericos - Google Patents

Dominios kunitz quimericos

Info

Publication number
PE20071314A1
PE20071314A1 PE2007000248A PE2007000248A PE20071314A1 PE 20071314 A1 PE20071314 A1 PE 20071314A1 PE 2007000248 A PE2007000248 A PE 2007000248A PE 2007000248 A PE2007000248 A PE 2007000248A PE 20071314 A1 PE20071314 A1 PE 20071314A1
Authority
PE
Peru
Prior art keywords
amino acids
kunitz
chemical domains
sequence
domains
Prior art date
Application number
PE2007000248A
Other languages
English (en)
Inventor
Felix Oehme
Heiner Apeler
Frank Dittmer
Juergen Franz
Axel Harrenga
Michael Sperzel
Simone Greven
Juergen Lenz
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20071314A1 publication Critical patent/PE20071314A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)

Abstract

REFERIDA A VARIANTES DEL DOMINIO 1 DEL INHIBIDOR 1 DEL FACTOR TISULAR HUMANO (hTFPI D1) DE FORMULA MHSFCAFKAX10X11GPCX15X16X17X18X19X20X21X22FNIFTRQCEEFIYGGCEGNQNRFESLEECKKMCTRD QUE TIENE UNA MUTACION EN LAS POSICIONES X10, X11, X15, X16, X17, X18, X19, X20, X21 Y X22 EN COMPARACION CON LA SECUENCIA NATURAL, DONDE X10 ES LOS AMINOACIDOS D, E, Y, V O S; X11 ES LOS AMINOACIDOS D O T; X15 ES LOS AMINOACIDOS K O R; X16 ES LOS AMINOACIDOS A; X17 ES LOS AMINOACIDOS I, R, S O A; X18 ES LOS AMINOACIDOS M, I, F O H; X19 ES LOS AMINOACIDOS K, I O P; X20 ES LOS AMINOACIDOS R; X21 ES LOS AMINOACIDOS F O W; X22 ES LOS AMINOACIDOS F O W, EXCEPTO EL PEPTIDO DE LA SECUENCIA SEC ID Nº1 (TFPI mut1). DICHAS VARIANTES INHIBEN LA PLASMINA Y LA CALICREINA EN EL PLASMA
PE2007000248A 2006-03-08 2007-03-07 Dominios kunitz quimericos PE20071314A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06004693 2006-03-08

Publications (1)

Publication Number Publication Date
PE20071314A1 true PE20071314A1 (es) 2008-02-24

Family

ID=38475215

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000248A PE20071314A1 (es) 2006-03-08 2007-03-07 Dominios kunitz quimericos

Country Status (16)

Country Link
US (1) US20090170766A1 (es)
EP (1) EP1994153A2 (es)
JP (1) JP2009528831A (es)
KR (1) KR20090009796A (es)
CN (1) CN101395274A (es)
AR (1) AR059789A1 (es)
AU (1) AU2007222621A1 (es)
BR (1) BRPI0708687A2 (es)
CA (1) CA2644255A1 (es)
DO (1) DOP2007000046A (es)
MX (1) MX2008011350A (es)
PE (1) PE20071314A1 (es)
RU (1) RU2008139632A (es)
TW (1) TW200813085A (es)
UY (1) UY30198A1 (es)
WO (1) WO2007101602A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008077478A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene
CN101402674B (zh) * 2008-10-20 2011-07-27 中国人民解放军第三军医大学 附睾蛋白酶抑制剂的功能肽段及应用
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
US10359175B2 (en) 2014-08-14 2019-07-23 Lg Chem, Ltd. Light-emitting film

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1489097E (pt) * 1994-01-11 2012-01-04 Dyax Corp Inibidores de plasmina humana derivados de domínios kunitz e ácidos nucleicos codificando os mesmos

Also Published As

Publication number Publication date
RU2008139632A (ru) 2010-04-20
BRPI0708687A2 (pt) 2011-06-07
WO2007101602A3 (en) 2007-12-13
UY30198A1 (es) 2007-10-31
JP2009528831A (ja) 2009-08-13
MX2008011350A (es) 2008-09-23
CA2644255A1 (en) 2007-09-13
EP1994153A2 (en) 2008-11-26
AU2007222621A1 (en) 2007-09-13
AR059789A1 (es) 2008-04-30
DOP2007000046A (es) 2007-09-30
WO2007101602A2 (en) 2007-09-13
TW200813085A (en) 2008-03-16
WO2007101602A9 (en) 2009-01-15
CN101395274A (zh) 2009-03-25
US20090170766A1 (en) 2009-07-02
KR20090009796A (ko) 2009-01-23

Similar Documents

Publication Publication Date Title
BRPI0602441B8 (pt) “método de fabricação de um artigo revestido tratado com calor"
CY1119723T1 (el) Φαρμακοτεχνικες μορφες πεπτιδιου περιεχουσες προπυλενογλυκολη οι οποιες ειναι βελτιστες για παραγωγη και για χρηση σε συσκευες ενεσεων
NO20025355L (no) Farmasöytisk preparat som omfatter en faktor VIIA og en faktor XIII
NL300808I2 (nl) susoctocog alfa
NZ607892A (en) Tfpi inhibitors and methods of use
DE502004006066D1 (de) Oberflächenmodifizierte pyrogen hergestellte Titandioxide
RS52537B (en) ACTIVIN-ACTRII ANTAGONISTS AND USES FOR ANEMIA TREATMENT
NO20034658D0 (no) LNG-produksjon i anlegg for kryogen behandling av naturgass
ECSP088614A (es) Composición de hipoclorito de calcio recubierta
NO20074824L (no) Forlengelse av tid til sykdomsprogresjon eller overlevelse hos kreftpasienter
EA200801945A1 (ru) Пирролотриазинанилиновые пролекарственные соединения, полезные в качестве ингибиторов киназы
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
PE20071314A1 (es) Dominios kunitz quimericos
BRPI0401482A (pt) Bico de mamadeira
ES2421447T3 (es) Métodos para proteger frente a apoptosis usando lipopéptidos
UY28641A1 (es) Anticuerpos
BRPI0512503A (pt) composição que compreende ácido lático e lactoferrina
UA98658C2 (uk) Циклічні депсипептиди
ATE443722T1 (de) Peptide und peptidderivate, ihre herstellung sowie ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
AR039664A1 (es) Composicion farmaceutica que comprende un inhibidor de lipasa y glucomanan
NO20084053L (no) Inhibering av tumorvekst
HUP0204551A2 (hu) Eljárás a pikkelysömör kezelésére
CY1105403T1 (el) Χρηση της ακετυλο-l-καρνιτινης σε συνδυασμο με τη βιοτινη για τη θepαπεια ασθενων με ινσουλινο-ανθεκτικο σακχαρωδη διαβητη τυπου 2
AR005797A1 (es) Trombinmuteinas como antidoto para los inhibidores de las trombinas
AR021241A1 (es) Inhibidores de proteasas

Legal Events

Date Code Title Description
FD Application declared void or lapsed